/Investor DB

Kairos Venture Partners — Full Portfolio

5 tracked investments · listed companies and verified rows first

Compelloncompellon.comJan 2018SEC filingmedium confidence

Rancho Santa Margarita, US

Mark Pollard(Executive Officer, Director)Kenneth Charhut(Executive Officer, Director)Nikolai Liachenko(Director)

BoardJerry Pellizzon(Director)

Board seatJames Demetriades· per SEC Form D · $2.3M raise · filed Feb 2018

Co-investorsKairos Venture Investments, Llc

Foldaxfoldax.comin𝕏Apr 2017SEC filingmedium confidence

Foldax develops heart valve replacement technology leveraging polymer expertise and biologic design.

Advanced ManufacturingBiotechHealthtechMedical DevicesSalt Lake City, US

Frank Maguire(Executive Officer, Director)

BoardKen Charhut(Director)George Wallace(Director)Morteza Gharib(Director)Mory Gharib(Director)

Board seatJames Demetriades· per SEC Form D · $9M raise · filed May 2017

Co-investorsAngel Physicians FundKairos Venture Investments, LlcMemorialCare Innovation FundBioStar CapitalBioStar VenturesSUMMATION HEALTH VENTURES

Linnaeus Therapeuticslinnaeustx.cominFeb 2026SEC filingmedium confidence

Clinical-stage biotech company developing small molecule agents modulating cellular differentiation for cancer and pigmentation disorders.

BiotechHaddonfield, US

Patrick T. Mooney(Executive Officer)in

BoardTodd Thomson(Director)inMichael D. Poisel(Director)Chris Arendt(Director)

Board seatJames Demetriades· per SEC Form D · $10M raise · filed Apr 2026

Co-investorsKairos Venture Investments, LlcIA Global

Proviviprovivi.comin𝕏Sep 2025SEC filingmedium confidence

AgTechSanta Monica, US

Frances Arnold(Director)inPeter Meinhold(Executive Officer)inPedro Coelho(Executive Officer)inCorey Huck(Executive Officer, Director)in

BoardGANESH KISHORE(Director)inALAN BOYCE(Director)

Board seatJames T Demetriades· per SEC Form D · $40M raise · filed Apr 2026

Co-investorsAliment CapitalKairos Venture Investments, LlcLanx CapitalPontifax AgTechSpruce Capital PartnersVivo Capital+1 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Gene Sciences

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.